Drug Search Results
More Filters [+]

Semagacestat

Alternative Names: semagacestat, ly450139
Latest Update: 2024-05-13
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: G-Secretase Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Eli Lilly
Company Location: INDIANAPOLIS IN 46285
Company CEO: David A. Ricks
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Semagacestat

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 3: Alzheimer Disease

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

2008-002758-39

P3

Completed

Alzheimer Disease

2011-07-11

LY450139 Versus Placebo

P3

Completed

Alzheimer Disease

2011-05-01

2009-014424-29

P3

Completed

Alzheimer Disease

2011-04-15

2007-005118-37

P3

Terminated

Alzheimer Disease

2011-04-12

Recent News Events